Adrenoleukodystrophy (ALD) Market to Grow Substantially During the Forecast Period (2022-32) - DelveInsight | Key Companies - POXEL SA (PXL770), bluebird bio, Minoryx Therapeutics, Orpheris

DelveInsight's "Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adrenoleukodystrophy Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Adrenoleukodystrophy market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Adrenoleukodystrophy (ALD): An Overview
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.

The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, which leads to the development of seizures and hyperactivity.

Adrenoleukodystrophy (ALD) Market Key Facts
As per DelveInsight, In 2017, the Adrenoleukodystrophy market size in the 7MM was USD 922.43 million, which is expected to grow by 2032.
In contrast to the US and EU-5 countries, the current therapeutic landscape of Adrenoleukodystrophy in Japan is driven by only SOCs.
In the US, the Standard of care (SOC) for managing ALD primarily includes supportive therapies (antiepileptic drugs, steroid supplementation, etc.).
Of the emerging therapies, Bluebird Bio, Minoryx Therapeutics, and Magenta Therapeutics are expected to enter the market, with their respective products, in different regions across the 7MM countries in the coming years.
In 2017, the total Adrenoleukodystrophy prevalent population in the 7MM was 55,200+.
Among the 7MM, the highest diagnosed prevalence of Adrenoleukodystrophy was observed in the United States, with 4,800+ cases in 2017.
Among the European 5 countries, Germany had the highest diagnosed prevalent population of ALD, with 1,600+ cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population in 2017.
As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries in 2017.

Adrenoleukodystrophy (ALD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Adrenoleukodystrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Adrenoleukodystrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Adrenoleukodystrophy Market will Grow by 2032:
https://www.delveinsight.com/report-store/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Adrenoleukodystrophy (ALD) Epidemiology
The epidemiology section covers detailed insights into the historical and current Adrenoleukodystrophy patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Adrenoleukodystrophy (ALD) Epidemiology Segmentation
Total Prevalent Population
Gender-specific Prevalence
Gender-specific Diagnosed Prevalent Population
Type-specific Diagnosed Prevalence of ALD

Get Key Insights Into the Evolving Adrenoleukodystrophy Epidemiology Trends:
https://www.delveinsight.com/report-store/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Adrenoleukodystrophy (ALD) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenoleukodystrophy market or expected to get launched in the market during the study period. The analysis covers the Adrenoleukodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Adrenoleukodystrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Some of the key companies in the Adrenoleukodystrophy (ALD) Therapeutics Market include:
• bluebird bio
• Applied Genetic Technologies Corporation
• Poxel
• Minoryx Therapeutics
• Orpheris
• MedDay Pharmaceuticals
• Magenta Therapeutics
• Viking Therapeutics
And many others

Adrenoleukodystrophy (ALD) Therapies covered in the report include:
• Lenti-D
• Leriglitazone
• MGTA-456
And many more

Learn More About the Emerging Therapies & Key Companies in the Adrenoleukodystrophy Therapeutics Market:
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Adrenoleukodystrophy Competitive Intelligence Analysis
4. Adrenoleukodystrophy Market Overview at a Glance
5. Adrenoleukodystrophy Disease Background and Overview
6. Adrenoleukodystrophy Patient Journey
7. Adrenoleukodystrophy Epidemiology and Patient Population
8. Adrenoleukodystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Adrenoleukodystrophy Unmet Needs
10. Key Endpoints of Adrenoleukodystrophy Treatment
11. Adrenoleukodystrophy Marketed Products
12. Adrenoleukodystrophy Emerging Therapies
13. Adrenoleukodystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Adrenoleukodystrophy Market Outlook (7 major markets)
16. Adrenoleukodystrophy Access and Reimbursement Overview
17. KOL Views on the Adrenoleukodystrophy Market.
18. Adrenoleukodystrophy Market Drivers
19. Adrenoleukodystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.